"DOJ Alleges Fraudulent Price Reporting by Regeneron Pharmaceuticals for Eylea Drug"

The United States has filed a complaint against Regeneron Pharmaceuticals, alleging that the company fraudulently manipulated Medicare reimbursement for its drug, Eylea, by knowingly submitting false average sales price (ASP) reports to Medicare. The complaint alleges that Regeneron inflated Eylea’s ASP by paying credit card processing fees for the benefit of physician-customers purchasing Eylea, without properly reporting these payments as price concessions to ASP, resulting in hundreds of millions of dollars in inflated reimbursements by Medicare. The government's investigation was prompted by False Claims Act allegations brought in a whistleblower lawsuit, and if found liable, Regeneron could face significant financial penalties.